Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
暂无分享,去创建一个
M. Lai | K. Yeh | A. Cheng | Y. Shao | Ho‐Min Chen | Zhong‐Zhe Lin | Kuo-Hsing Chen | Yu-Lin Lin